Laxmi Dental has uploaded the audio recording of its Q1FY27 earnings conference call to its corporate website, providing investors with access to management’s commentary on the quarter’s performance. The call took place on August 12, 2026, at 11:00 A.M. (IST), following the company’s quarterly results announcement. This move ensures transparency and allows stakeholders to review the detailed financial discussion and strategic updates provided by the executive team.

The disclosure is made pursuant to Regulation 30(6), read with Schedule III Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Laxmi Dental Limited informed both the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the availability of the recording. The audio file is hosted directly on the company’s investor relations page.

Call Details

Suman Saha, Company Secretary and Compliance Officer of Laxmi Dental Limited, signed the intimation letter sent to the listing departments of BSE and NSE. The filing references the company’s ISIN INE0WO601020 and confirms that the recording is accessible via the specific URL provided in the regulatory submission. Investors are advised to visit the website for the complete audio content.

Laxmi Dental reported a 23.8% year-on-year increase in consolidated net profit to ₹103.15 million for the quarter ended June 30, 2026 (Q1FY27), driven by significant growth in its aligners business segment. The Mumbai-based dental products manufacturer saw consolidated revenue from operations rise 13.6% to ₹729.91 million, reflecting strong demand across its product lines. EBITDA for the quarter grew to ₹144 million from ₹120 million in the year-ago period, with EBITDA margin expanding to 19.68% from 18.66%. This financial performance was approved by the Board of Directors at a meeting held on August 11, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The statutory auditors, MSKA & Associates LLP, conducted a limited review of the unaudited standalone and consolidated financial results under Standard on Review Engagements (SRE) 2410. The audit firm issued an unmodified opinion on the statements, which were prepared in accordance with Indian Accounting Standard 34 ('Interim Financial Reporting'). The Board also noted the execution of a Letter of Intent for the proposed acquisition of land situated at Palghar, Maharashtra, for a total consideration of ₹6.21 crore, aimed at expanding business operations through factory construction.

Financial Performance Highlights

The company's top-line growth was supported by both its core laboratory business and its expanding aligners division. While the laboratory business revenue declined slightly quarter-on-quarter, the aligners business showed substantial momentum. Key financial metrics for the quarter are detailed below:

Consolidated profit before tax increased 25.5% to ₹120.41 million from ₹95.95 million in the corresponding period last year. Other income contributed ₹22.98 million, up from ₹17.22 million previously. Total expenses stood at ₹649.53 million, compared to ₹577.24 million in Q1FY26, primarily due to higher employee benefit expenses and purchases of stock-in-trade.

Segment-Wise Analysis

The Chief Operational Decision Maker monitors performance across three segments: Laboratory Business, Aligners Business, and Other Business. The Aligners Business emerged as the primary growth engine, with revenue surging 29.1% year-on-year to ₹241.69 million. In contrast, the Laboratory Business, which remains the largest contributor, saw revenue decline 7.9% to ₹502.81 million.

The Aligners Business segment result improved dramatically to ₹65.33 million from ₹22.79 million in Q1FY26, highlighting operational leverage in this high-growth category. The Laboratory Business segment result was ₹76.98 million, down from ₹101.54 million in the prior year period.

What the Numbers Show

A notable divergence exists between revenue trends and profitability drivers across segments. While the Laboratory Business generated higher absolute revenue, its contribution to segment profit decreased significantly. Conversely, the Aligners Business, though smaller in revenue scale, delivered a disproportionate boost to overall profitability, with segment results nearly tripling year-on-year. The improvement in EBITDA margin to 19.68% from 18.66% further underscores the improving margin profile in the aligners division, potentially offsetting softness in the traditional laboratory products.

Corporate Developments and IPO Utilization

Beyond financial results, the Board approved the allotment of 59,360 equity shares to eligible employees upon exercise of options vested under the Laxmi Dental Stock Option Scheme 2024. The paid-up equity share capital increased from 5,49,62,149 shares to 5,50,21,509 shares. Additionally, the Board took note of the surrender of 1,636 employee stock options by Mr. Ansari Mohammed Saad, Senior Executive Technical Support.

Regarding capital allocation, the company has utilized ₹779.72 million of its initial public offer proceeds as of June 30, 2026, against a total requirement of ₹1,281.70 million. The unutilized amount of ₹501.98 million is temporarily invested in fixed deposits with banks. The company is currently seeking an extension for the utilization of these IPO proceeds in subsequent periods. The Board also reaffirmed the Scheme of Merger involving wholly-owned subsidiary Bizdent Devices Private Limited, which awaits requisite statutory approvals.